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Coronary CT Angiography Versus Standard Emergency Department
Evaluation for Acute Chest Pain and Diabetic Patients: Is There
Beneﬁt With Early Coronary CT Angiography?
Results of the Randomized Comparative Effectiveness ROMICAT II Trial
Quynh A. Truong, MD, MPH; Joshua Schulman-Marcus, MD; Pearl Zakroysky, MPH; Eric T. Chou, MD; John T. Nagurney, MD, MPH;
Jerome L. Fleg, MD; David A. Schoenfeld, PhD; James E. Udelson, MD; Udo Hoffmann, MD, MPH; Pamela K. Woodard, MD
Background-—Cardiac computed tomography angiography (CCTA) reduces emergency department length of stay compared with
standard evaluation in patients with low- and intermediate-risk acute chest pain. Whether diabetic patients have similar beneﬁts is
unknown.
Methods and Results-—In this prespeciﬁed analysis of the Rule Out Myocardial Ischemia/Infarction by Computer Assisted
Tomography (ROMICAT II) multicenter trial, we randomized 1000 patients (17% diabetic) with symptoms suggestive of acute
coronary syndrome to CCTA or standard evaluation. The rate of acute coronary syndrome was 8% in both diabetic and nondiabetic
patients (P=1.0). Length of stay was unaffected by the CCTA strategy for diabetic patients (23.9 versus 27.2 hours, P=0.86) but
was reduced for nondiabetic patients compared with standard evaluation (8.4 versus 26.5 hours, P<0.0001; P interaction=0.004).
CCTA resulted in 3-fold more direct emergency department discharge in both groups (each P≤0.0001, P interaction=0.27). No
difference in hospital admissions was seen between the 2 strategies in diabetic and nondiabetic patients (P interaction=0.09). Both
groups had more downstream testing and higher radiation doses with CCTA, but these were highest in diabetic patients
(all P interaction≤0.04). Diabetic patients had fewer normal CCTAs than nondiabetic patients (32% versus 50%, P=0.003) and
similar normalcy rates with standard evaluation (P=0.70). Notably, 66% of diabetic patients had no or mild stenosis by CCTA with
short length of stay comparable to that of nondiabetic patients (P=0.34), whereas those with >50% stenosis had a high prevalence
of acute coronary syndrome, invasive coronary angiography, and revascularization.
Conclusions-—Knowledge of coronary anatomy with CCTA is beneﬁcial for diabetic patients and can discriminate between lower
risk patients with no or little coronary artery disease who can be discharged immediately and higher risk patients with moderate to
severe disease who warrant further workup.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identiﬁer: NCT01084239. ( J Am Heart Assoc. 2016;5:
e003137 doi: 10.1161/JAHA.115.003137)
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D iabetes mellitus (DM) is an important risk factor forthe development and severity of coronary artery
disease (CAD). Although DM is considered a coronary
heart disease risk equivalent for guiding preventive
therapies,1 many diabetic patients do not have obstructive
CAD.2 As such, the presence of DM has not been found to
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be diagnostically helpful in the setting of acute chest
pain.3–6
Cardiac computed tomography angiography (CCTA) is an
advanced noninvasive imaging modality with excellent diag-
nostic accuracy for the detection of CAD. Three large
multicenter randomized trials have shown that CCTA imple-
mented early in the emergency department (ED) for the
evaluation of acute chest pain was associated with reduced
length of stay (LOS) and was a safe alternative compared with
standard ED evaluation.7–9 These ﬁndings were driven mostly
by CCTA’s high negative predictive value for ruling out CAD by
direct visualization of the coronary arteries, especially in low-
risk patients.10 It is unknown whether these ﬁndings apply to
patients with DM in light of their higher pretest probability of
CAD.
In this prespeciﬁed analysis from the Rule Out Myocardial
Ischemia/Infarction by Computer Assisted Tomography
(ROMICAT II) trial, we aimed to determine whether patients
with DM and higher cardiovascular risk have beneﬁts similar
to patients without DM. Speciﬁcally, we compared the
differences in effectiveness and safety, including downstream
testing and radiation exposure, between an early CCTA and
standard evaluation in patients with and without DM who
presented to the ED with chest pain suggestive of acute
coronary syndrome (ACS).
Methods
Study Population and Protocol
The randomized multicenter ROMICAT II trial enrolled 1000
patients at 9 US sites who presented to the ED during
weekday daytime hours with symptoms suggestive of ACS but
without ischemic ECG changes or initial positive troponin.
Details on the study design, inclusion and exclusion criteria,
and primary results have been reported previously.7,11 Brieﬂy,
inclusion criteria were patient age of 40 to 74 years, chest
pain or anginal equivalent of at least 5-minute duration within
24 hours of ED presentation, sinus rhythm, and warranting
further risk stratiﬁcation to rule out ACS. The major exclusion
criteria were known CAD, new ischemic changes on the ECG,
initial troponin in >99th percentile of the local assay, impaired
renal function with creatinine >1.5 mg/dL, hemodynamic or
clinical instability, allergy to iodinated contrast agent, body
mass index (in kg/m2) >40, or currently symptomatic
asthma. The trial was approved by the institutional review
board at each participating site, and all participants provided
informed consent.
Patients were randomized in a 1:1 fashion to either CCTA
or standard ED evaluation strategy, as dictated by local health
care providers. CCTA was performed with at least 64-slice
computed tomography technology and either retrospectively
ECG-gated or prospectively ECG-triggered CCTA protocols.
The standard ED evaluation strategy included no testing,
functional testing (exercise treadmill test, exercise or phar-
macological nuclear imaging, stress echocardiography), or
invasive coronary angiography. All imaging studies were
interpreted by the local sites. Patients were contacted by
telephone within 72 hours if discharged within 24 hours of
ED presentation to evaluate for potential missed ACS.
Patients were followed for 28 days after discharge by
telephone interview and were questioned regarding repeated
ED visits or hospitalizations for recurrent chest pain,
diagnostic testing or interventions, and major adverse cardiac
events. In this analysis, we focused on comparing differences
between patients with and without DM regarding the effec-
tiveness and safety of implementing an early CCTA strategy
versus standard ED evaluation. DM was deﬁned by self-report
if the patient had diabetes that required or did not require
insulin and/or was taking either insulin or oral hypoglycemics,
according to the medical history form.
End Points
The primary end point was LOS, deﬁned as the time from ED
presentation to the time of the discharge order from either
the ED or the hospital. Secondary effectiveness end points
included rates of direct ED discharge (deﬁned as the
proportion of patients discharged from the ED without
admission to an observation unit or hospital), hospital
admission, downstream testing (deﬁned as ≥2 diagnostic
tests, which included CCTA, exercise treadmill test, nuclear
stress test, stress echocardiography, transthoracic echocar-
diography, and invasive coronary angiography), rates of
invasive coronary angiography, revascularization (percuta-
neous coronary intervention and/or coronary arterial bypass
grafting), and repeated ED visit or hospitalization for recurrent
chest pain at 28 days. Safety end points included cumulative
radiation exposure (in mSv) from CCTA, nuclear perfusion
imaging, and invasive coronary angiography, calculated using
standard methods12 during the index evaluation and follow-
up; missed ACS, deﬁned as an unexpected cardiovascular
event within 72 hours after hospital discharge in patients with
a hospital stay of <24 hours; and major adverse cardiac
events, deﬁned as death, myocardial infarction, unstable
angina, or urgent coronary revascularization that occurred
within 28 days of the initial ED visit.
Statistical Analysis
Descriptive statistics were expressed as meanSD or median
with interquartile range for continuous variables and as
frequency and percentages for categorical variables. To
compare differences between groups, we used the Fisher
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exact test for categorical variables and the Student t test for
continuous variables, as appropriate. We used logistic
regression to test the interaction between DM and random-
ized evaluation strategies for binary outcomes and analysis of
variance or quantile regression for continuous outcomes, as
appropriate. For adjusted analyses of the diabetes interaction
with randomized ED strategies on mean and median LOS, we
controlled for variables with differences (P<0.05) between
patients with and without diabetes, including age, race,
ethnicity, cardiac risk factors (sex, hypertension, dyslipidemia,
family history of premature CAD, systolic blood pressure, and
body mass index), and medications (aspirin, beta blockers,
statins). We used the Student t test to compare the mean
effective radiation dose between groups and ANOVA to test
the interaction between diabetes and randomized evaluation
strategies. Two-tailed P and P interaction values of <0.05
were considered to indicate statistically signiﬁcance. All




Overall, 173 (17%) patients had DM and 827 (83%) did not.
Of the 501 patients in the CCTA arm, 86 had DM and 415
were nondiabetic. Of the 499 patients in the standard
evaluation arm, 87 had DM and 412 were nondiabetic.
Among the patients with DM, 70% were on oral hypo-
glycemics and 25% were on insulin. Table 1 depicts the
baseline characteristics of the ROMICAT II trial participants
stratiﬁed by DM. Diabetic patients were older, were more
frequently black and female, had additional cardiovascular
risk factors (especially hypertension and dyslipidemia), took
more cardiac medications (aspirin, beta blockers, and
statins), and had higher body mass index than patients
Table 1. Baseline Characteristics of Patients by Diabetes
Diabetes No Diabetes P Value
Patients, n (%) 173 (17) 827 (83)
Demographics
Age, y, meanSD 57.08.2 53.68.0 <0.0001
Female sex (%) 96 (55) 372 (45) 0.01
Race
Black (%) 64 (37) 218 (26) 0.01
White (%) 90 (52) 570 (69) <0.0001
Asian (%) 9 (5) 22 (3) 0.09
Other (%) 11 (6) 19 (2) 0.01
Ethnicity, Hispanic or Latino
(%)
32 (19) 95 (11) 0.01
Cardiovascular risk factors
Hypertension (%) 152 (88) 389 (47) <0.0001
Dyslipidemia (%) 128 (74) 326 (39) <0.0001
Former or current smoking
(%)
79 (46) 413 (50) 0.32
Family history of premature
CAD (%)
36 (21) 235 (28) 0.05
Number of risk factors (%) <0.001
0 or 1 2 (1) 371 (45)
2 or 3 100 (58) 428 (52)
≥4 71 (41) 28 (3)
Relevant prior medication
Aspirin, n (%) 81 (47) 147 (18) <0.0001
Beta blocker, n (%) 50 (29) 120 (15) <0.0001
Statins, n (%) 92 (53) 202 (24) <0.0001
Insulin, n (%) 44 (25) 0 (0) <0.0001
Oral hypoglycemics, n (%) 121 (70) 0 (0) <0.0001
Initial ED presentation
Chief complaint 1.00
CP with or without
radiation (%)
156 (90) 740 (90)
Pain in arm, jaw,
shoulder, or epigastric
(%)
6 (3) 31 (4)
Shortness of breath (%) 3 (2) 14 (2)
Other (%) 8 (5) 42 (5)







Body mass index, kg/m2 31.54.9 28.85.0 <0.0001
Serum creatinine, mg/dL 0.840.22 0.870.19 0.21
Continued
Table 1. Continued




Noncardiac CP (%) 144 (83) 727 (88)
Noncoronary CP (%) 5 (3) 10 (1)
Coronary CP, not ACS (%) 11 (6) 28 (3)
ACS (%) 13 (8) 62 (8) 1.00
Unstable angina pectoris
(%)
11 (6) 41 (5)
Myocardial infarction (%) 2 (1) 21 (3)
ACS indicates acute coronary syndrome; bpm, beats per minute; CAD, coronary artery
disease; CP, chest pain; ED, emergency department.
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No Diabetes, n=412) P Value P interaction
Primary end point
Length of stay, hours
Diabetes, meanSD 32.243.2 32.020.1 0.97 0.08/0.004*
Median* [25th, 75th percentile] 23.9 [6.7, 32.9] 27.2 [23.8, 31.2] 0.86
No diabetes, meanSD 21.335.3 30.629.4 <0.0001
Median* [25th, 75th percentile] 8.4 [6.3, 25.7] 26.5 [20.0, 30.2] <0.0001
Secondary end points
Direct ED discharge
Diabetes, n (%) 34 (40) 12 (14) 0.0001 0.27
No diabetes, n (%) 205 (49) 54 (13) <0.0001
Hospital admission
Diabetes, n (%) 30 (35) 25 (29) 0.41 0.09
No diabetes, n (%) 78 (19) 101 (25) 0.05
Downstream testing
Index visit
Diabetes, n (%) 33 (38) 4 (5) <0.0001 0.001
No diabetes, n (%) 83 (20) 49 (12) 0.002
At 28-day follow-up
Diabetes, n (%) 36 (42) 6 (7) <0.0001 0.002
No diabetes, n (%) 97 (23) 54 (13) 0.0001
Invasive coronary angiography
Index visit
Diabetes, n (%) 16 (19) 5 (6) 0.01 0.06
No diabetes, n (%) 38 (9) 31 (8) 0.45
At 28-day follow-up
Diabetes, n (%) 17 (20) 6 (7) 0.01 0.08
No diabetes, n (%) 42 (10) 34 (8) 0.40
PCI
Index visit
Diabetes, n (%) 6 (7) 2 (2) 0.17 0.41
No diabetes, n (%) 18 (4) 12 (3) 0.35
At 28-day follow-up
Diabetes, n (%) 6 (7) 2 (2) 0.17 0.37
No diabetes, n (%) 21 (5) 15 (4) 0.40
PCI/CABG at 28 days
Diabetes, n (%) 7 (8) 2 (2) 0.10 0.26
No diabetes, n (%) 25 (6) 18 (4) 0.35
Repeat ED/hospitalizations for CP
Diabetes, n (%) 0 (0) 4 (5) 0.25 0.97
No diabetes, n (%) 14 (3) 15 (4) 0.55
Continued
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without DM (all P≤0.01). Patients with and without DM had
the same rate of ACS as a ﬁnal diagnosis (8% for both,
P=1.0). In addition, there was no difference in ACS rate by
diagnostic strategy (P=0.23). The differences in demograph-
ics were not statistically signiﬁcant between treatment
groups for patients with and without DM (all P interactions
≥0.05) (Appendix).
Primary and Secondary Effectiveness End Points
Table 2 shows differences in end points between evaluation
strategies in participants with and without DM. Among DM
patients, mean and median LOS were not statistically
signiﬁcantly different with either strategy, whereas the CCTA







No Diabetes, n=412) P Value P interaction
Safety end points
Cumulative radiation exposure (mSv)
Diabetes, meanSD 18.414.7 6.610.4 <0.0001 0.04
No diabetes, meanSD 13.49.8 5.19.5 <0.0001
Missed ACS
Diabetes, n (%) 0 (0) 0 (0) — —
No diabetes, n (%) 0 (0) 0 (0) —
28-day MACE
Diabetes, n (%) 0 (0) 1 (1) 1.0 0.97
No diabetes, n (%) 2 (0.5) 5 (1.2) 0.29
ACS indicates acute coronary syndrome; CABG, coronary artery bypass grafting; CCTA, cardiac computed tomography angiography; CP, chest pain; ED, emergency department; MACE,
major adverse cardiovascular events; PCI, percutaneous coronary intervention.
*P interaction for median length of stay.
Table 3. Effective Radiation Dose (in mSv) by Randomization Strategy and Initial Testing Modality With Radiation Exposure and the
Cumulative 28-Day Dose Stratiﬁed by Diabetes
Diabetes No Diabetes
P Valuen (%) MeanSD n (%) MeanSD
ETT, n=140 25 (18) 115 (82)
Initial ETT test 0 0 —
Index visit 0.00.0 1.85.2 0.0003
28-day follow-up 0.83.9 2.77.4 0.06
Nuclear stress test, n=116 27 (23) 89 (77)
Initial nuclear test 16.55.2 13.54.2 0.002
Index visit 16.55.2 14.46.3 0.11
28-day follow-up 16.55.2 14.46.3 0.11
Stress echo, n=106 19 (18) 87 (82)
Initial stress echo test 0 0 —
Index visit 0.21.1 0.21.1 0.82
28-day follow-up 0.21.1 0.21.1 0.82
CCTA, n=474 79 (17) 395 (83)
Initial CCTA test 10.84.7 9.75.0 0.07
Index visit 16.412.8 12.19.2 0.006
28-day follow-up 17.214.3 12.49.5 0.005
CCTA indicates cardiac computed tomography angiography; echo, echocardiography; ETT, exercise treadmill test.
DOI: 10.1161/JAHA.115.003137 Journal of the American Heart Association 5
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without DM over standard ED evaluation (mean D9.4 hours, P
interaction=0.08; median D12.2 hours, P interaction=0.004).
This difference in median LOS persisted after adjustments for
covariates that were different between DM and non-DM
patients (P interaction<0.0001).
Direct ED discharge was similarly 3 times as high with
early CCTA as with standard evaluation in both DM and
non-DM groups (both P≤0.0001, P interaction=0.27). There
was no signiﬁcant difference in hospital admissions
between DM and non-DM groups (P interaction=0.09),
although a trend was seen toward fewer admissions for
non-DM patients in the CCTA arm compared with the
standard ED arm (P=0.05). Downstream testing at both the
index visit and at 28-day follow-up was more common in
the CCTA arm in both DM and non-DM participants, and
this difference was accentuated in those with DM (P
interaction≤0.002). Although there was no signiﬁcant
difference in the use of invasive coronary angiography in
DM versus non-DM patients (P interaction=0.06), we
observed a 3-fold higher rate of cardiac catheterization
with the early CCTA strategy in DM patients (P=0.01) that
was not seen in those without DM (P=0.45). In addition,
there were no differences in revascularization rate with
percutaneous coronary intervention and/or coronary artery
bypass grafting or repeated ED visit or hospitalization for
recurrent chest pain with either ED strategy or diabetes
status (all P interactions≥0.26). There was no difference
in mean total cost of stay between diabetic and nondiabetic




The early CCTA strategy resulted in higher estimated cumu-
lative radiation exposure by 28-day follow-up in both the DM
group (18.4 versus 6.6 mSv; P<0.0001) and the non-DM
group (13.4 versus 5.1 mSv; P<0.0001), with even slightly
higher radiation in DM than non-DM patients (P interac-
tion=0.04) (Table 2).
Table 3 summarizes the effective radiation dose by initial
testing modality and subsequent testing stratiﬁed by diabetes
status. Among patients using the CCTA strategy, DM patients
had radiation exposure during their index CCTA scan similar
to non-DM patients (P=0.07); ultimately, however, they
incurred higher radiation exposure than non-DM patients
during index hospitalization and follow-up (both P≤0.006). In
the standard ED arm, among patients with an initial nuclear
stress test, DM patients had an initially higher radiation dose
than non-DM patients (P=0.002), but this difference was
attenuated at the index visit or 28-day follow-up (both
P=0.11). Of note, DM patients who underwent a nuclear
stress test ﬁrst had comparable radiation exposure by 28-day
follow-up as those who had an initial CCTA test (16.5 versus
17.2 mSv, P=0.71).
Missed ACS and major adverse cardiac events
There was no missed ACS event in the trial. There was no
interaction between diabetes status and randomized ED
strategy for 28-day major adverse cardiac events (interaction
P=0.97), although the number of events was very small in
each group.
Initial Diagnostic Testing Results
Table 4 shows the test results stratiﬁed by diabetes status.
Patients with DM were less likely to have a normal CCTA (32%
versus 50%, P=0.003) and had a higher rate of obstructive
CAD with severe stenosis (19% versus 9%, P=0.02) than those
without DM. In contrast, among the 346 patients with
functional testing in the standard evaluation arm, patients
with and without DM had similar rates of normal results (83%
versus 85%, P=0.70).
Table 4. Initial Diagnostic Testing Results Stratiﬁed by





CCTA (n=473), n 79 394 0.005
No CAD (%) 25 (32) 198 (50) 0.003
Mild (1–49%) stenosis (%) 27 (34) 122 (31) 0.60
Moderate (50–69%) stenosis
(%)
7 (9) 22 (6) 0.30
Severe (≥50% LM or ≥70%)
stenosis (%)
15 (19) 37 (9) 0.02
Indeterminate (%) 5 (6) 15 (4) 0.35
Standard evaluation arm
Any diagnostic testing (n=346), n* 66 280
Normal (%) 55 (83) 239 (85) 0.70
ETT (n=138) 24 114
Normal (%) 23 (96) 106 (93) 1.0
Nuclear (n=108), n 24 84
Normal (%) 18 (75) 68 (81) 0.57
Stress echo (n=100), n 18 82
Normal (%) 14 (78) 65 (79) 1.0
CAD indicates coronary artery disease; CCTA, cardiac computed tomography
angiography; echo, echocardiography; ETT, exercise treadmill test; LM, left main.
*Includes ETT, nuclear, and stress echo.
DOI: 10.1161/JAHA.115.003137 Journal of the American Heart Association 6
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CCTA Subgroup Analysis
Table 5 shows the LOSs of patients with and without DM, as
categorized by their CCTA ﬁndings. Notably, 66% of diabetic
patients who underwent CCTA had either no CAD or mild
nonobstructive stenosis of <50% (32% no CAD and 34% mild
[1–49%] stenosis on CCTA). For these patients, median LOS
was short, <8 hours, and similar to the LOS of their non-DM
counterparts (all P values not signiﬁcant) (Figure). Similar
results of short LOS were found when limiting the comparison
between DM and non-DM for those with normal CCTA
(P=0.21). When examining the drivers of LOS using CCTA
Table 5. Length of Stay and Rates of Acute Coronary Syndrome, Invasive Coronary Angiography, and Revascularization During
Index Visit Based on CCTA Results Stratiﬁed by Diabetes Status
Diabetes No Diabetes P Value
Length of stay, hours
No CAD (n=223) n=25 n=198
MeanSD 10.28.4 13.731.1 0.21
Median [25th, 75th percentile] 7.0 [5.4, 9.0] 7.1 [5.8, 9.5] 0.89
Mild (1–49%) stenosis (n=149) n=27 n=122
MeanSD 23.633.1 13.212.2 0.12
Median [25th, 75th percentile] 8.6 [6.5, 28.5] 8.0 [6.2, 19.7] 0.71
Moderate (50–69%) stenosis (n=29) n=7 n=22
MeanSD 35.616.8 39.031.6 0.71
Median [25th, 75th percentile] 36.3 [27.6, 54.6] 28.7 [20.6, 49.0] 0.38
Severe (≥50% LM or ≥70%) stenosis (n=52) n=15 n=37
MeanSD 81.873.0 70.864.3 0.61
Median [25th, 75th percentile] 49.3 [29.2, 101.7] 50.1 [30.4, 76.8] 0.98
Indeterminate (n=20) n=5 n=15
MeanSD 33.810.9 28.425.6 0.52
Median [25th, 75th percentile] 28.2 [26.7, 35.5] 24.8 [11.0, 28.2] 0.76
Acute coronary syndrome
No CAD (n=223) 0 1 (0.5) 1.0
Mild (1–49%) stenosis (n=149) 0 0 —
Moderate (50–69%) stenosis (n=29) 1 (14) 2 (9) 1.0
Severe (≥50% LM or ≥70%) stenosis (n=52) 6 (40) 27 (73) 0.05
Indeterminate (n=20) 0 1 (7) 1.0
Invasive coronary angiography
No CAD (n=223) 0 2 (1) 1.0
Mild (1–49%) stenosis (n=149) 1 (4) 2 (2) 0.45
Moderate (50–69%) stenosis (n=29) 3 (43) 6 (27) 0.64
Severe (≥50% LM or ≥70%) stenosis (n=52) 11 (73) 24 (65) 0.75
Indeterminate (n=20) 0 2 (13) 1.0
Revascularization with PCI or CABG
No CAD (n=223) 0 1 (0.5) 1.0
Mild (1–49%) stenosis (n=149) 0 0 —
Moderate (50–69%) stenosis (n=29) 1 (14) 2 (9) 1.0
Severe (≥50% LM or ≥70%) stenosis (n=52) 5 (33) 17 (46) 0.23
Indeterminate (n=20) 0 1 (7) 1.0
CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; CCTA, cardiac computed tomography angiography; LM, left main; PCI, percutaneous coronary intervention.
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results, having >50% stenosis and indeterminate examina-
tions resulted in a minimum of an overnight stay for both
DM and non-DM patients (Table 5). As expected, DM
patients with >50% stenosis by CCTA had high prevalence
of ACS, invasive coronary angiography, and revasculariza-
tion (Table 5).
Discussion
In this analysis of the ROMICAT II trial, patients with DM had
similar LOS when early CCTA was used in the ED evaluation
compared with standard ED evaluation of acute chest pain
suggestive of ACS. In contrast, patients without diabetes had
reduced LOS by a median of 12 hours with an early CCTA
strategy compared with standard ED evaluation. Although all
patients in the early CCTA arm had 3-fold more direct ED
discharges, there was also increased downstream testing and
unwanted higher cumulative radiation exposure, which were
accentuated among those with DM, despite similar cost
differences between strategies. Importantly, two-thirds of DM
patients who underwent CCTA had no or mild CAD and
beneﬁted from short LOS similar to their non-DM counterpart.
The efﬁcient diagnosis and management of diabetic
patients with acute chest pain and without known CAD has
remained a challenge for decades. Prior studies of such
patients have not found the presence of diabetes or other
cardiovascular risk factors to be predictive of ACS.3–6
Nevertheless, given the association between CAD and DM,
it is likely that many physicians feel uncomfortable discharg-
ing diabetic patients without time-consuming conﬁrmatory
testing. Older literature found that diabetic patients with
acute chest pain were more likely to be hospitalized than
nondiabetic patients.3 Although a strategy of using resting
myocardial perfusion imaging in patients with acute chest
pain reduced hospital admissions,13 this was not found to be
true in diabetic patients.14 CCTA has demonstrated great
promise in reducing LOS and hospital admissions for patients
with acute chest pain,7–9 largely as a result of the excellent
negative predictive value of a normal scan. CCTA studies
comparing diabetic and nondiabetic patients, however, have
consistently demonstrated higher rates of plaque, plaque
severity, obstructive CAD, and multivessel CAD in the former
group.15–17 In ROMICAT II, patients without diabetes had a
median 12-hour reduction in LOS if early CCTA was used
compared with standard ED evaluation. Regardless of dia-
betes status, patients with >50% stenosis by CCTA rightfully
required an overnight stay with >24 hours in the hospital and
had a high prevalence of ACS as well as greater use of
invasive coronary angiography and revascularization. The
decrease in efﬁciency of LOS in diabetic patients may be
explained by the increased prevalence and severity of CAD, as
detected by CCTA, over their non-DM counterparts.
In contrast, the surprisingly high prevalence of diabetic
patients in the CCTA arm who had no or mild CAD of <50%
stenosis by CCTA is noteworthy. These DM patients
accounted for two-thirds of those scanned; had a median
short LOS of <8 hours, similar to nondiabetic patients; and
had a 3-fold increase in direct ED discharge compared with
those in the standard ED arm. Although the attenuation of
LOS reduction in diabetic patients reﬂects a clinically relevant
increase in testing to identify those at higher risk with
moderate to severe CAD, those without obstructive disease
are effectively discharged home from the ED. Our ﬁndings
provide support and should reassure health care providers
that although DM patients have higher rates of CAD than
patients without DM,15–17 a large proportion have no or mild
CAD and can be discharged from the ED.
Limitations
Our study had several notable limitations. Patients with
diabetes composed only 17% of the sample, and the overall
number of major adverse events was low. The interactions
between diabetes status and treatment on the secondary or
safety end points were unadjusted because of the limitations
of having few events in our study; therefore, the interaction
may not be due to diabetes but to a confounding variable. This
prevalence of diabetes, however, is similar to that in other
large randomized CCTA trials. In addition, the tradeoff for
increased CAD detection by CCTA is likely greater utilization
of downstream testing,7 which is especially prominent in
diabetic patients, although the trial was not designed to
Figure. Length of stay for patients with no or mild coronary
atherosclerosis (<50% stenosis) by cardiac computed tomography
angiography, stratiﬁed by diabetes. DM indicates diabetes mellitus;
ED, emergency department.
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capture the outcomes of downstream interventions or longer
follow-up periods beyond 28 days. Another limitation to CCTA
implementation is increased radiation exposure, which was
accentuated among patients with DM in ROMICAT II; however,
compared with DM patients who underwent nuclear imaging
ﬁrst, those who underwent CCTA ﬁrst incurred similar
radiation exposure. The radiation dose exposure reported
for CCTA in ROMICAT II is higher than is typical in current
practice, given the availability of newer imaging acquisition
protocols and scanner technology. More recent improvements
in CCTA technology have reduced radiation doses to submil-
lisievert ranges,18,19 so the increased radiation dose may be
most relevant for those with moderate to severe CAD, who
will likely incur downstream tests and procedures that
requires ionizing radiation, such as nuclear imaging or cardiac
catheterization.
Conclusion
In ED patients with acute chest pain, an early CCTA strategy
compared with standard ED evaluation was associated with
shorter LOS in nondiabetic patients but similar LOS in diabetic
patients. Nevertheless, two-third of diabetic patients had no or
mild coronary atherosclerosis by CCTA and beneﬁted similarly
with short LOS and high rate of direct ED discharge. Direct
visualization of higher prevalent CAD by CCTA may explain the
increased downstream testing and radiation exposure with
CCTA that were accentuated in patients with diabetes. Knowl-
edge of coronary anatomy with CCTA is beneﬁcial for the DM
cohort and can discriminate between lower risk patientswith no
or little CADwho can be discharged immediately and higher risk
patients with moderate to severe disease who warrant further
investigation and therapy.
Appendix
Baseline Characteristics of Patients by Diabetes and Randomized ED Strategies
Diabetes No Diabetes
P interactionCCTA Arm Standard ED Evaluation CCTA Arm Standard ED Evaluation
n (%) 86 (17) 87 (17) 415 (83) 412 (83)
Demographics
Age, y (meanSD) 56.68.5 57.47.9 53.57.9 53.88.0 0.75
Female (%) 46 (53) 50 (57) 193 (47) 179 (43) 0.40
Race
Black (%) 30 (35) 34 (39) 111 (27) 107 (26) 0.53
White (%) 43 (50) 47 (54) 287 (69) 283 (69) 0.59
Asian (%) 6 (7) 3 (4) 12 (3) 10 (2) 0.51
Other (%) 7 (8) 4 (5) 5 (1) 14 (3) 0.05
Ethnicity, Hispanic or Latino (%) 17 (20) 15 (17) 42 (10) 53 (13) 0.33
Cardiovascular risk factors
Hypertension (%) 78 (91) 74 (85) 191 (46) 198 (48) 0.21
Dyslipidemia (%) 67 (78) 61 (70) 163 (39) 163 (40) 0.27
Former or current smoking (%) 36 (42) 43 (49) 213 (51) 200 (49) 0.22
Family history of premature CAD (%) 14 (16) 22 (25) 121 (29) 114 (28) 0.13
Number of risk factors (%) 0.95
0 to 1 0 (0) 2 (2) 182 (44) 189 (46)
2 to 3 54 (63) 46 (53) 217 (52) 211 (51)
≥4 32 (37) 39 (45) 16 (4) 12 (3)
Relevant prior medication
Aspirin, n (%) 40 (47) 41 (47) 75 (18) 72 (17) 0.85
Beta blocker, n (%) 24 (28) 26 (30) 64 (15) 56 (14) 0.53
Continued
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